Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Investigator-Sponsored Phase Ib Trial of Venetoclax and SINE: Selective Inhibition of Nuclear Export in Patients with High Risk Hematologic Malignancies

NCT03955783 is registered in ClinicalTrials.gov with Sanjay Mohan as lead sponsor.

NCT NCT03955783
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03955783 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Investigator-Sponsored Phase Ib Trial of Venetoclax and SINE: Selective Inhibition of Nuclear Export in Patients with High Risk Hematologic Malignancies
Lead sponsor
Sanjay Mohan
Phase
Phase 1
Overall status
Completed
Start date
June 21, 2019
Completion date
September 1, 2024
Enrollment
78 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, diffuse large b-cell lymphoma, non-hodgkin's lymphoma